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Background: Several studies have demonstrated the benefit of Cystic Fibrosis Newborn Screening (CFNBS) for early diagnosis and, hence,
intervention but the impact of CFNBS on those children not detected on CFNBS is not known. CFNBS may provide false reassurance that all CF
has been detected and, therefore, lead to a delay in the diagnosis of children with CF which is not detected on CFNBS. The aim of this study was
to determine the impact of CFNBS on the presenting features of children with CF where CF was not detected on CFNBS.
Methods: Subjects at the CFNBS center were selected if CF was identified subsequent to a negative CFNBS with subjects at the No CFNBS
selected based on the absence of ΔF508 mutations. Children presenting with features that would lead to investigation for CF independent of
clinical status were excluded. Presenting features at diagnosis and pulmonary function at 6 years of age were extracted from medical records.
Results: Twelve children from the CFNBS site and 19 from the No CFNBS site were included in the analysis. The only significant difference between
the two in features at diagnosis was lower mean weight z-scores at the NoCFNBS site (−2.9±1.8) compared to the CFNBS center (−1.4±1.3, pb0.05).
Age at diagnosis, presenting complaint and nutritional status did not differ by site. Growth parameters and pulmonary function at 6 years of age showed
no differences between sites.
Conclusions: This study demonstrates that access to CFNBS does not result in delay in diagnosis or poorer outcomes in those children for whom
CF was not detected on CFNBS. In addition, children with CF not detected on CFNBS present with typical features of CF and sweat chloride
results that are diagnostic of CF.
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Cystic Fibrosis Newborn Screening (CFNBS) has been
implemented in many countries over the last 25 years including
Australia and New Zealand [1,2], the Netherlands [3], and parts
of Europe [4–7], the United Kingdom [8], and the United States
[9–11]. Alberta was the first province in Canada to start CFNBS
with province wide screening beginning in April 2007 [12]. The⁎ Corresponding author at: Division of Respiratory Medicine, Department of
Pediatrics, Faculty of Medicine & Dentistry, 7317A Aberhart Centre, 11402
University Avenue NW, Edmonton, AB, Canada T6G 2J3. Tel.: +1 780 407
3302; fax: +1 780 407 8283.
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doi:10.1016/j.jcf.2011.04.002method for screening has evolved from employing a single
radioimmunoassay for immunoreactive trypsin (IRT) to the
current method for most centers of using a combination of IRT
and deoxyribonucleic acid (DNA) analyses [13]. The sensitivity
of newborn screening for the detection of Cystic Fibrosis (CF)
will differ depending on the IRT cut off as well as the
population screened as a result of differences in the genotypic
distribution for CF in that population, with estimates of false
negative results ranging from 1.7–5.4% of children with CF
[14–17].
The presence of CFNBSmay lead to a false reassurance that all
children with CF have been identified as newborns [18]. This
reassurance may result in a delay of the diagnosis of those
children with CF for whom CF is not detected on CFNBS. Delayd by Elsevier B.V. All rights reserved.
Table 1
Demographic characteristics of the sample by site — identification of ‘missed’
CF.
Variable CFNBS site No CFNBS site
N 21 25
Identified CF causing mutations:
None 6 (28%) 8 (32%)
One 8 (38%) 4 (16%)
Two 7 (33%) 13 (52%)
Presenting features meet exclusion criteria:
Positive double IRT on NBS 7 (33%) Not applicable
Family history of CF 0 4 (16%)
Meconium ileus 2 (9%) 2 (8%)
Included in analysis 12 19
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with deleterious outcomes including nutritional and growth
concerns [19,20], a higher rate of complications [21], increased
stress and frustration to the families [22], and the potential for
poorer pulmonary outcomes [1,23,24].While several studies have
demonstrated the benefit of CFNBS for early diagnosis and hence
intervention, the impact of CFNBS on those children not detected
on CFNBS has not been compared to similar groups in centers
where CFNBS is not available.
The aim of this study was to determine the impact of CFNBS
on the detection of CF in children where CF is not detected on
CFNBS by comparing the presenting features of children with
CF for whom CF was not detected on CFNBS to children with
similar CF genetics at a center where CFNBS was not in place.
The hypothesis was that CFNBS confers reassurance that CF is
diagnosed in the newborn period and, therefore, leads to a delay
in the diagnosis of CF in those children where CF is not detected
on CFNBS. The results will highlight the presentation of the
small group of children with CF where CF is not detected on
CFNBS.
2. Method
Subjects for this study were selected from the clinic
populations of two publically funded pediatric tertiary care
centers who provide comprehensive care for children with CF
between the ages of 0 and 18 years. In the CFNBS site, CFNBS
has been available since 1981. Initially, a double immunoreactive
trypsinogen (IRT) approachwas used where all newborns with an
IRT N99th centile had a repeat IRT at 6–8 weeks of age. Since
1992 CFNBS has employed an initial IRT with subsequent DNA
mutational analyses for ΔF508 based on a predetermined cut-off
IRT (IRT N99th centile). In order to identify a comparable group
of children with CF at the second center (No CFNBS) where
CFNBS was not in place at the time of the study, subjects were
identified based on the absence ofΔF508mutations.Approval for
this study was obtained from the Human Research Ethics
Committee at The Children's Hospital at Westmead (Westmead,
NSW, Australia) and the Human Research Ethics Board at the
Hospital for Sick Children (Toronto, ON, Canada).
The CFNBS center had a clinic population of 284 children and
the No CFNBS site had a clinic population of 215 at the time of
the study. Review of all current CF clinic patients was completed
using the CF database and CF clinic charts in addition to medical
records at each site. Data extracted included clinical features at the
time of diagnosis (age at diagnosis, chief complaint, sweat
chloride, genotype, growth parameters, nutritional parameters,
need for admission, sputum microbiology and radiological
findings) as well as pulmonary function testing and growth
parameters closest to 6 years of age. Children with presenting
features that would lead to the investigation of CF independent of
clinical status were excluded from further analysis. This included
a positive double IRT on NBS, a family history of CF and
meconium ileus (MI).
Weight and height z-scores were calculated using the
information available from the Centre for Disease Control
(http://www.cdc.gov/nccdphp/dnpa/growthcharts/sas.htm).Sweat testing was completed at both centers using pilocarpine
iontophoresis [25]. Pancreatic insufficiency was defined as a fecal
fat on 72 hour fecal fat collection of N10% for children less than
6 months or N6% for children greater than 6 months or a stool
elastase b100 μg/g of stool. Respiratory microbiology specimen
collectionwas completed by throat swab, auger suction, or sputum
collection (including induced sputum production) with only the
results from routine CF microbiology plating included in this
study. The predicted values for spirometry and lung volume
measurements were computed using the appropriate reference
equations for each gender [26].
Statistical analyses were completed using SPSS 13.0.1
(SPSS Inc., 1989–2004). T-tests were used for comparison on
continuous variables with categorical variables compared
using Pearson Chi-square and comparison of medians using
Mann–Whitney U test. A p-value of less than 0.05 was
considered to demonstrate a significant difference between the
groups.3. Results
Forty-six children with a diagnosis of CF and no ΔF508
mutation were identified from the two clinical sites (21 CFNBS
site, and 26 No CFNBS site). Of these children, 15 had clinical
features that met exclusion criteria which left 31 children to be
included in the analysis; 12 from the CFNBS center and 19 from
the No CFNBS center (Table 1). Eighteen different genotypes
were identified with 3 common to both sites (Table 2).
The mean age at diagnosis for the 31 patients included in the
analysis was 19.3±26.9 months with a mean age of 27.5±
37.2 months at the CFNBS site and 14.1±16.9 at the No CFNBS
site (Table 3; p=0.25). All but two children presented with typical
symptoms of CF; at the No CFNBS site one child presented with
pseudomonas sepsis and intensive care admission and one child
presented with hyponatremia, hypokalemia and hypomagnese-
mia. All children had sweat chlorides diagnostic for CF with a
minimum sweat chloride of 74 mmol/L. The only presenting
feature that was significantly different between the sites was
weight z-score where the CFNBS site had a higher mean z-score
compared to theNoCFNBS site. One child at the CFNBS site had
failure to thrive at diagnosis compared to 10 children at the No
CFNBS site (chi-square 6.9, pb0.01).
Table 2
Cystic fibrosis genotypes by site. Genotypes are listed as common to both sites
or unique to one site with the number of children with each genotype indicated in
brackets. Eighteen genotypes were identified with 17% of genotypes common to
both sites.
Sites CFNBS center No CFNBS center
Common Other/Other (3)
G542×/Other (2)
G551D/Other (1)
Other/Other (6)
G542×/Other (1)
G551D/Other (1)
CFNBS site N1303K/Other (1)
21833AA-NG/21833AA-NG (1)
3695delC/621+1 G-NT (1)
D1507/G551D (1)
G542×/G551D (1)
N1303K/G551D (1)
No CFNBS
site
W1282X/W1282X (3)
1525-1 GNA/Other (1)
1677delTA/1898+2 TNC (1)
G551D/V520F (1)
G551D/N1303K (1)
G85E/Other (1)
L218X/L218X (1)
N1303K/R560T (1)
R334W/1898+1 GNA (1)
Table 3
Summary of presenting features at the time of diagnosis of CF by site. The only
variable that demonstrated a statistically significant difference by site was
weight z-score.
Variable CFNBS site No CFNBS site p values
N 12 19
Mean age at diagnosis (months) 27.5±37.2 14.1±16.9 0.25
Median age at diagnosis (months) 10.2 7.4 0.78
Presenting features: 0.26
Failure to thrive (FTT) 5 4
Respiratory symptoms 3 4
Gastrointestinal symptoms
without FTT
2 2
Respiratory & Gastrointestinal
symptoms
1 7
Other a 0 2
Not available 1 0
Sweat chloride (mmol/L;SD) 92.7±17.5 101.0±18.0 0.23
Weight z-score † −1.4±1.3 −2.9±1.8 0.027
Height z-score −1.6 ±5.3 −2.1±1.5 0.75
Vitamin A (μmol/L) 1.0±0.5 0.7±0.5 0.31
Vitamin E (μmol/L) 7.8±8.1 6.9±6.0 0.78
Albumin (g/dL) 31.9±7.5 29.5±7.1 0.42
Pancreatic insufficiency 57% 73% 0.45
a Other: one child presented with pseudomonas sepsis requiring an intensive
care admission, one child presented with hyponatremia, hypokalemia and
hypomagnesiumia.
† pb0.05.
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and were abnormal for 10 children at the CFNBS site and 18
children at the No CFNBS site (chi-square 1.1, p=0.30). Ten
children from the CFNBS site and 11 children from the No
CFNBS site had respiratory tract microbiology performed at
diagnosis. From these children, either Staphlococcus aureus or
Pseudomonas aeruginosa was isolated from 8 children from the
CFNBS site and 7 children at the No CFNBS site (chi-square
0.69, p=0.41).
Data after 6 years of age was available for 8 children from the
CFNBS site and 16 children from the No CFNBS site (Table 4).
There was no significant difference by site for FEV1, weight or
height. For 2 children from the CFNBS site, spirometry and lung
volume data were available at 12 and 15 years of age. Excluding
these children did not change the results of the analyses for any
measure at follow-up.
4. Discussion
This study demonstrates that access to CFNBS does not delay
the diagnosis of CF in those children for whom CF was not
detected on CFNBS. It also supports the premise that children
with CF without a ΔF508 mutation are likely to present with
typical features of CF and sweat chlorides that are diagnostic of
CF. Finally, our results suggest that, for this select group of
children, at 6 years of age both lung function and growth
parameters are similar in the CFNBS and No CFNBS sites.
Limitations of this study need to be considered in the
interpretation and application of the results. Firstly, we identified
subjects in our No CFNBS center based on the absence of a
ΔF508 mutation because our CFNBS center employs single
mutational analysis as part of CFNBS. While this criterion led to
comparable groups for our study populations, our results may not
generalize to centers where a mutational panel is employed as partof CFNBS. Secondly, because we chose to compare the current
clinic populations of single centers where, excluding CFNBS,
both diagnostic and treatment practices are similar, our numbers
were small which would lead to wide confidence intervals around
estimates. However, overall the group differences were not
consistent with poorer outcomes in the late diagnoses in the
CFNBS center. With larger numbers, group differences at
diagnosis may be statistically different for a later age at diagnosis
and a lower frequency of pancreatic insufficiency in the CFNBS.
Finally, incomplete follow-up from both groups at 6 years of age
further limited our sample size at this age.
The population of children with CF who will be missed in
places where CFNBS is in place is small. The false negative rate
reported for the Australian CFNBS program after 10 years of
experience was 5% [15] with similar rates reported from the
United States (1.7%) and France (3.4%) [16,17]. CF mutations
vary by race and, hence, different regions will tailor their
CFNBS approach to the CF characteristics of their population.
For example, the reported frequency of the delta F508 mutation
in Australia is 76.9% and in Toronto, Canada is 70.9% with an
estimated detection of two CF causing mutations of 78.7% and
67.2% respectively [26]. Our results support the premise that the
presentation and outcomes of CF in those children not detected
by CFNBS is likely to be similar, despite some variation in the
underlying mutations responsible for CF.
Age of diagnosis of CFwill be influenced by both the type and
severity of clinical features. In a study of 19,956 children who
were part of the CF Foundation registry data 1986–2000, a
positive family history or MI were associated with a younger age
of diagnosis (39.7±79.6 and 11.0±45.5 months respectively).
Table 4
Clinical features at 6 years of age by site. There were no statistically significant
differences between the sites for any clinical features at 6 years of age.
Variable CFNBS site No CFNBS site p values
N 8 16
Age at lung function (years) 8.3±3.6 6.3±0.8 0.17
FEV1 (L) 1.5±1.0 1.0±0.4 0.26
FEV1 (%predicted) 93.4±30.3 85.3±21.6 0.46
Weight z-score −0.58±1.57 −0.55±1.25 0.97
Height z-score −0.42±0.73 −0.33±0.96 0.82
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age of diagnosis of 45.6±86.8 months and a median 9.7 months
[27]. Children who presented with nutritional symptoms of CF
were diagnosed at an earlier age than those presenting with
respiratory symptoms. Subgroup analysis limited to children
diagnosed after 1986 supported that advances in other areas of CF
care have not lead to similar improvements in early diagnosis of
symptomatic children with CF. The Wisconsin Cystic Fibrosis
Neonatal Screening Project reported a mean age of CF diagnosis
of 60.1±89.8 weeks (approx 14 months) with a median age of
22.0 weeks (approx 5 months) in 31 children who did not
undergo screening for CF [20]. The results from the present study,
while smaller in numbers and different in methodology, support a
median age of diagnosis under 1 year with a mean age of
diagnosis under 2 years.
Multiple factors, including age of diagnosis, will affect the
survival of children and adults with CF. Using the CF Foundation
registry data, Lai and colleagues [27] examined factors affecting
survival of children including the mode of diagnosis, age of
diagnosis and presenting features at diagnosis in addition to the
effect of treatment changes by subgroup analysis. Compared to
those diagnosed on CFNBS, children with CF with symptomatic
presentation or MI had a 1.73 (95% CI=1.21–2.47, p=0.003)
and a 1.75 (95% CI=1.22–2.50) times higher risk of shortened
survival. However, when the analysis was restricted to those
diagnosed after 1986 only the difference between children
diagnosed on CFNBS and those presenting with MI remained
statistically significant (hazard ration 2.37, 95% CI=1.24–4.52).
Children presenting with respiratory and/or nutrition symptoms
independently also showed a higher risk of shortened survival
compared to those diagnosed by CFNBS. This and other studies
have demonstrated that the effect of age of diagnosis on survival
with CF is complex [4,27] because age of diagnosis will be
influenced by the severity of CF. For example, in a 30 year
retrospective review of survival with CF from two regions in Italy
including diagnosis by symptoms and screening, those diagnosed
after 5 years of age appeared to have a survival advantage over
those diagnosed under 1 year of age without a significant effect of
screening on survival but a positive effect of diagnosis after 1983
compared to earlier years [4]. Analysis of the CF Foundation
Registry data also demonstrated a positive association between
later diagnosis and higher survival in the complete data set with
subgroup analyses demonstrating similar survival for those
diagnosed by screening or symptoms under 1 month of age
with a survival advantage for diagnosis by either method under1 month compared to symptomatic diagnosis over 1 month of age
[27].While our study was not designed to assess the impact of
CFNBS on survival of children with CF not detected by CFNBS,
age of diagnosis is clearly not the only factor affecting survival
with CF. CF mutation differences are likely to impact the
detection by CFNBS, the age of diagnosis as well as the
subsequent clinical course and long term survival.
While there is considerable discussion of the implication of
false positive results on CFNBS, little attention has been given
to those children with false negative CFNBS. A case series
reporting the clinical presentation of 6 children missed on
CFNBS includes two children who were indeed detected by
CFNBS but because of administrative issues the parents or
guardians were not made aware of these results [18]. All
presented with typical features of CF including failure to thrive,
respiratory tract infections and/or gastrointestinal complaints. In
a study of diagnostic stories of 40 families where the diagnosis
of CF was delayed, Kharrazi and colleagues [22] illustrate the
family perspective through a single imaginary family. From this
study, the authors concluded that the age at whichCF is diagnosed
can have a large impact on a number of facets of their life
including quality of life, longevity, compliance with medical
regimens and family structure. While a study of the impact of
false–positive CFNBS found that no concern of parental
perception of child vulnerability 11–14 years after testing [28],
long termparental guilt where diagnosis was delayedwas difficult
to avert or remove later. While the current study does not explore
the psychological impact of CF not detected on CFNBS, it does
provide evidence that children with CF not detected by CFNBS
are unlikely to be negatively impacted as compared to children
with similar CF genetics living in areas where CFNBS is not
available.
In summary, the results from this study demonstrate that
CFNBS does not negatively impact the detection of CF in
children with CF where the detection of CF is not made on
CFNBS. While this group of children with CF is small, the
expansion of CFNBS warrants further attention to the long term
implications of CF not detected on CFNBS.
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